Metabolomic profile as a biomarker in early breast cancer patients candidate to neoadjuvant therapy

被引：0
|
作者：
Martini, V. [1 ]
Ruffilli, B. [2 ]
Di Lascio, S. [1 ]
D'Avanzo, F. [1 ]
Rossi, V. [1 ]
Gobbato, S. [2 ]
Vezzoli, F. [2 ]
Negrini, L. [2 ]
Alsati, R. [2 ]
Ben Ayed, R. [2 ]
Tarantino, G. [3 ]
Guarneri, V. [4 ]
Griguolo, G. [4 ]
Boldorini, R. L. [2 ]
Branni, C. [2 ]
Matera, L. [2 ]
Sala, N. [2 ]
Barberis, E. [2 ]
Manfredi, M. [2 ]
Gennari, A. [2 ]
机构：
[1] AOU Maggiore Carita, Dept Oncol, Novara, Italy
[2] Univ Piemonte Orientale, Translat Med, Novara, Italy
[3] Pharmanutra Spa, Pisa, Italy
[4] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 200卷
关键词：
D O I：
10.1016/j.ejca.2024.113874
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
308 (PB-12
引用
收藏
页码：115 / 115
页数：1
相关论文
共 50 条
  • [21] Gut Microbiota Predict Efficacy of Neoadjuvant Systemic Therapy in Patients with Early Breast Cancer
    Ross, K.
    Nichols, B.
    Papadopoulou, R.
    Macleod, M.
    Fraser, J.
    Barrett, S.
    Teo, K.
    Mallon, E.
    Ammar, A.
    Edwards, J.
    Evans, J.
    Gerasimidis, K.
    Macpherson, I.
    CLINICAL ONCOLOGY, 2024, 36 (04) : E107 - E108
  • [22] Neoadjuvant therapy increases the risk of metabolic disorders and osteosarcopenia in patients with early breast cancer
    Zhang, Yan
    Kang, Hua
    Zhao, Jing
    Wang, Yajun
    Cai, Wei
    Zhang, Xiaoli
    Li, Kaifu
    Zhao, Ye
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (09) : 959 - 966
  • [23] Biomarker alterations in ER-positive breast cancer patients who undertook neoadjuvant endocrine therapy
    Hayama, S.
    Nakamura, R.
    Sangai, T.
    Nagashima, T.
    Ohtsuka, M.
    Yamamoto, N.
    BREAST, 2017, 32 : S79 - S79
  • [24] Neoadjuvant therapy with celecoxib to women with early stage breast cancer
    Tfayli, A.
    Yang, J.
    Kojouri, K.
    Kesserwan, C.
    Jafari, M.
    Ozer, H.
    NEOPLASMA, 2008, 55 (02) : 122 - 126
  • [25] Neoadjuvant everolimus as a targeted therapy for early stage breast cancer
    Xu, Bing
    Williams, Casey
    Leyland-Jones, Brian
    CANCER RESEARCH, 2017, 77
  • [26] EARLY RESULTS OF NEOADJUVANT (PREOPERATIVE) THERAPY OF BREAST-CANCER
    RAGAZ, J
    CANCER INVESTIGATION, 1986, 4 (05) : 502 - 502
  • [27] Prognostic Significance of Biomarker Discordance in Breast Cancer Patients with Neoadjuvant Chemotherapy
    Matsumoto, Akiko
    Yoshikawa, Mio
    Takahashi, Yoko
    Jinno, Hiromitsu
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] Prognostic significance of biomarker discordance in breast cancer patients with neoadjuvant chemotherapy
    Matsumoto, A.
    Yoshikawa, M.
    Jinno, H.
    ANNALS OF ONCOLOGY, 2017, 28 : 19 - 19
  • [29] GDF-15 is a potential candidate biomarker for an elevated risk of cardiotoxicity in breast cancer patients receiving neoadjuvant dual anti-HER2 therapy
    Tian, Chunyu
    Zhang, Hongxu
    Liu, Jianping
    Xu, Mengze
    Ma, Lihui
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [30] Cost-effectiveness analysis of VEGF-C: A novel predictive biomarker for response to bevacizumab in the neoadjuvant therapy of early breast cancer patients
    Blank, Patricia Renee
    Loibl, Sibylle
    Linderholm, Barbro Kristina
    Caramuta, Stefano
    Nekljudova, Valentina
    Szucs, Thomas D.
    van Stiphout, Joris
    Ademi, Zanfina
    Von Minckwitz, Gunter
    Schwenkglenks, Matthias
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345